AMARANTUS BIOSCI INC (OTC:AMBS) On the Rise Again

84LOGO.pngThe tough year for Amarantus Biosciences Inc (OTC:AMBS) is continuing. It all started when their stock prices plummeted in the first half of January. They fell from $0.18 per share to right around $0.070.

Since then the prices haven’t managed to rise, but have been gradually going down instead. The stock reached an all-time low of $0.055 in the beginning of April. However, the tendency is changing and prices are now going up.

13AMBS_chart.pngThis movement in stock prices can be attributed to a few factors, the first of which would most probably be recent press releases and promotional emails. Unfortunately these press releases aren’t saying anything different from what we heard from AMBS in the last 6 months.

Each press release tells of the company’s future plans and opportunities to produce a drug that will help patients with Parkinson’s and a variety of other conditions, based on a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF).

While this might mislead people that have recently heard of AMBS and are interested in their stock, the folks that took their piece of the pie a long time ago are starting to see that there is not much going on with the so called research. This might be the reason why the stock has been gradually falling down since January.

Many people have waited a considerable amount of time to see a result of the company’s research and are now selling at lower prices in fear of the stock’s diminishing price flows. Another thing that is alarming is the amount of shares that have been issued in the past year, diluting the stock value.

On the one hand, we can conclude that investing in AMBS at this moment seems rather risky. On the other hand, if you look at buying stock from them in a charitable way and as “helping science find cure for unfortunate diseases” you might be interested. However, we can’t guarantee on the matter of how that money is going to be spent, be it for covering the currently accumulated debt or for actual research.

You may also like...